Home › Acute Lung Injury › NCT07125079

Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

Blood-based Biomarkers of Acute Lung Injury/Acute Respiratory Distress Syndrome

Who can join

Ages 21 to 90 · All sexes

Inclusion Criteria: ARDS patients with mild and moderate to severe ARDS. This will be based on PaO2/FiO2 in the range of 100 mmHg (severe) and moderate (100-200 mm Hg) and mild (200-300 mm Hg) -

Exclusion Criteria: Pregnant women, children will be excluded.

\-

About the study

Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) is a condition where high levels of inflammation damage the lung. This is a highly morbid condition with no specific pharmacologic therapies. The investigators posit that ARDS is caused due to an exaggerated activation of immune cells and that blockade of this activation may reduce lung damage/injury and help in ARDS management and possibly recovery. To test this hypothesis, the investigators propose to generate an in vitro immune cell model and test a novel (reactive oxygen species) blocking agent PIP-2 on this model. The investigating team will obtain blood of ARDS patients and isolate immune cells (specifically peripheral blood mononuclear cells or PBMC) and monitor the activation of these cells and their blockade by PIP-2. This is entirely an in vitro study.

Sponsor: University of Pennsylvania · Participants: 36 · Started: May 20, 2025

Contact the study team

• Shampa Chatterjee, PhD · Phone: 215-898-9101
• Christian Bermudez, MD · Phone: 215-615-5864

Official record on ClinicalTrials.gov — NCT07125079

Locations in the U.S.

Conditions

• Acute Lung Injury

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.